Rutgers NJMS Logo

Department of Surgery

Andrew N. De la Torre, M.D.

Fellow of the American College of Surgeons

Associate Professor

Department of Surgery
delatoan@njms.rutgers.edu
 
DOC

Doctor's Office Center (DOC)
90 Bergen Street Room 7100
Newark, NJ 07101
Phone: (973) 972-0607
Fax: (973) 972-9401

Clinical Info

Medical Expertise

1) Liver, Pancreas & Bile duct Surgery (Minimal access, Laparoscopic & open)
2) Clinical trials in cancers of the liver and pancreas.

 

Hospital Affiliation

University Hospital, Newark
Overlook Hospital
St. Michael's Medical Center - Newark

 

Insurance Participation

Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.

Last Updated:

 

Languages

Spanish

 

Biography

Overview

Medical Degree
Johns Hopkins School of Medicine
Baltimore, Maryland
Class of 1989

BA, Chemistry
Queens College, CUNY
Flushing, New York
Class of 1984

Surgical Training
New Jersey Medical School
University Hospital
Newark, New Jersey
UMDNJ
1990-1995

Fellowship Training
Kidney and Pancreas transplant
University of Maryland Medical Systems
Baltimore, Maryland
1995-1998

Liver transplant
New Jersey Medical School
University Hospital
Newark, New Jersey
1999-2000

 

Education

M.D., 1989, Johns Hopkins University School of Medicine

 

Licensure & Certification

Medical Licensure
New Jersey

 

Languages

Spanish

 

Publications

Relevant Publications:

Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon S, Marotta P, Vierling J, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b Dose-Ranging Study of PEG- Interferon-Lambda Plus Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Hepatology. 2010 May 14
Abushahba W, Lasfar A , Balan M, Castaneda I, Yuan Y, Prescott L, Reuhl K, Raveche E, de la Torre AN, Kotenko SV. Antitumor Activity of Type I and Type III Interferons in BNL Hepatoma Model. Cancer Immunol Immunother. 2010 Mar 9
Ferrante JM, Winston DG, Chen PH, de la Torre AD Family Physicians’ Knowledge and Practices Regarding Chronic Hepatitis and Monitoring for Liver Cancer. Family Medicine Family Medicine 2008 May: 40(5), 345-351
Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, Wachsberg RH, de la Torre AN, Debroy M, Fisher A, Wilson DJ, Samanta AK. The ischemic preconditioningparadox in deceased donor liver transplantation-evidence from a prospectiverandomized single blind clinical trial. Am J Transplant. 2007 Dec;7(12):2788-96.
Abujudeh H, Contractor D, delaTorre A, Koneru B. Rescue TIPS in acute Budd-Chiari syndrome. AJR Am J Roentgenol. 2005 Jul;185(1):89-91
Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ, de la Torre AN. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2005 Feb;27(2):192-8
Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005 Feb;11(2):196-202
Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, dela Torre A, Samanta A, Korogodsky M. Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg. 2004 Sep;139(9):992-6
Fisher A, Seguel JM, de la Torre AN, Wilson D, Merchant A, Arora RK, Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl. 2004 Feb;10(2):193-8
16. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, dela Torre AN, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for Hepatocellular carcinoma. J Am Coll Surg J Am Coll Surg. 2003 Nov; 197(5): 759-64

 

Current Research

Immunotherapy Against Cancers in the Liver

My work focuses on immune stimulation to fight primary and metastatic cancers in the liver. There are 2 main
protocols. The first (clinicaltrials.gov Protocol ID NCT00553683) uses autologous prime-boost anti-tumor vaccination
in patients with hepatomas or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the
liver. This is a phase I/IIa clinical trial using 1) low dose cyclophosphamide to reduce tumor driven immune tolerance,
2) low dose radiation to the tumor, to increase expression of tumor antigens, 3) injection of an immune stimulant, TLR
III agonist Poly IC:LC, into and around the tumor to activate the body’s immune defenses, and 4) tumor ablation to
reduce production of tumor promoting and immunosuppressive factors. This is referred to as “Priming”. Patients are
then subject to systemic administration of POLY ICLC to “Boost” the anti-tumor immune response.

The second (clinicaltrials.gov Protocol ID NCT01387555) uses an oncolytic poxvirus, or vaccinia virus (JX-594) that are
highly selective to attack cancers and have minimal side effects, limited to flu-like symptoms. The (JX-594 strain
backbone of has been used safely in millions of people as part of a worldwide vaccination program. Features include 1)
rapid and motile spread in tumors (increased potency), 2) intravenous stability and delivery to solid tumors, 3)
therapeutic transgene-arming capacity, and 4) antidotes are available (to maximize safety). JX-594 is an engineered
oncolytic virus designed to selectively destroy cancer cells through three diverse mechanisms of action: 1) the lysis of
cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and
destruction, and 3) the stimulation of the body's immune response against cancer cells. JX-594 exploits a specific
genetic feature in cancer cells to become activated and lyse the cells, including the EGFR-ras signaling pathway, the cell
cycle activation and the loss of cellular interferon defenses. JX-594 is a Wyeth vaccinia virus with a disruption of the viral
thymidine kinase (tk) gene and expression of the immunostimulatory cytokine, GM-CSF (granulocyte macrophage
colony-stimulating factor).



 

 

Everything A Medical School Should Be - And More

© 2014, Rutgers, The State University of New Jersey. All rights reserved.

185 South Orange Avenue, Newark, New Jersey 07101